Clinical Trial Detail

NCT ID NCT02200380
Title A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors Celldex Therapeutics
Indications

non-Hodgkin lymphoma

chronic myeloid leukemia

Hodgkin's lymphoma

chronic lymphocytic leukemia

bone marrow cancer

acute lymphocytic leukemia

acute myeloid leukemia

Therapies

Plerixafor

CDX-301

Age Groups: adult

No variant requirements are available.